Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RedHill Biopharma ( (RDHL) ) has shared an update.
RedHill Biopharma disclosed that on April 8, 2026 it received a notice from Nasdaq stating its American Depositary Shares had closed below the $1.00 minimum bid price requirement for continued listing for 30 consecutive business days between February 20 and April 2, 2026. Under Nasdaq rules, the company has until October 5, 2026 to regain compliance, during which time its ADSs will continue to trade on the Nasdaq Capital Market and its ongoing operations remain unaffected, though the notice underscores continued pressure on its share price and poses a potential delisting risk if the issue is not remedied.
RedHill’s ability to restore its bid price above the $1.00 threshold for at least ten consecutive business days will determine whether it maintains its listing status, a key factor for liquidity and access to U.S. capital markets. The development may prompt the company to consider strategic options such as operational milestones or capital structure measures to support the share price, decisions that will be closely watched by investors concerned about regulatory compliance and longer-term financing flexibility.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
Score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a partial offset with improving short-term trend and momentum, but longer-term trend and MACD remain unsupportive. Valuation impact is neutral due to missing P/E and dividend yield.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company listed on Nasdaq under the ticker RDHL. The company focuses on developing and commercializing proprietary therapies, primarily in the gastrointestinal and infectious disease markets, targeting unmet medical needs in the U.S. and other global markets.
Average Trading Volume: 43,873
Technical Sentiment Signal: Sell
Current Market Cap: $4.2M
For detailed information about RDHL stock, go to TipRanks’ Stock Analysis page.